Drug
Alirocumab
Alirocumab: highest development phase Post-Market, developed by Regeneron, Sanofi, United Therapeutics. 4 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Regeneron, Sanofi, United Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| Alirocumab NCT03750760 | Post-Market | Myocardial Infarction |
| Alirocumab NCT01644188 | Phase 3 | Hypercholesterolemia |
| Alirocumab NCT01623115 | Phase 3 | Hypercholesterolemia |
| Alirocumab NCT03507374 | Phase 1 | Stroke |
Latest
No recent events.
Follow Alirocumab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.